Panbela announces publication of preclinical and clinical data titled: inhibition of polyamine biosynthesis preserves Β cell function in type 1 diabetes

Minneapolis, nov. 02, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces the publication of preclinical and clinical data from studies of cpp-1x (also known as Α-difluoromethylornithine (dfmo) or eflornithine) in recent onset type 1 diabetes (t1d). according to sims et al, although therapy of t1d has improved, the morbidity, mortality and cost continue to impact the quality of life for those affected highlighting the need for safe and effective therapies that address the underlying pathology. data published in the journal cell reports medicine investigated the mechanism of polyamines and polyamine inhibition by cpp-1x on Β cell stress that plays a role in the onset of type 1 diabetes in in vitro and ex vivo models. results showed that dfmo treatment may preserve Β cell function, reflected by c-peptide levels in patients with t1d through the modulation of urinary polyamines, in particular putrescine. the work reflects the company's ongoing collaboration with indiana university school of medicine. a link to the publication can be found here: https://www.cell.com/cell-reports-medicine/fulltext/s2666-3791(23)00438-x.
PBLA Ratings Summary
PBLA Quant Ranking